TrialBritish journal of cancer2017
Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial.
Roberto Pili et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
60 papers cite it
this papertrialcites it